​

Aprea Therapeutics Stock (NASDAQ:APRE)

ForecastRevenueOwnershipFinancialsChart
Aprea Therapeutics by TradingView

Previous Close

$0.83

52W Range

$0.55 - $2.69

50D Avg

$0.81

200D Avg

$1.33

Market Cap

$4.97M

Avg Vol (3M)

$2.21M

Beta

1.55

Div Yield

-

APRE Company Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Oct 03, 2019

Website

APRE Performance

APRE Financial Summary

Dec 24Dec 23Dec 22
Revenue-$583.23K-
Operating Income$-14.32M$-15.47M$38.18M
Net Income$-12.96M$-14.29M$-224.88M
EBITDA$-14.32M$-14.28M$-112.48M
Basic EPS$-2.35$-3.95$-2.71K
Diluted EPS$-2.35$-3.95$-2.71K

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
HCWBHCW Biologics Inc.
CELZCreative Medical Technology Holdings, Inc.
RNAZTransCode Therapeutics, Inc.
APVOAptevo Therapeutics Inc.
INABIN8bio, Inc.
ACXPAcurx Pharmaceuticals, Inc.
KPRXKiora Pharmaceuticals, Inc.
ADILAdial Pharmaceuticals, Inc.
BCDABioCardia, Inc.
GLTOGalecto, Inc.